ライフサイエンスコーパス: currently licensed

1 ive and longer-lasting protection than those currently licensed.

2 a stand-alone vaccine or in combination with currently licensed adjuvants for lymphoma immunotherapy.

3 Currently licensed and approved malaria subunit vaccines

4 Many currently licensed and commercially available human vacc

5 ered survey to 800 physicians and 800 nurses currently licensed and practicing in Minnesota.

6 c than TFT, which is the only effective drug currently licensed and routinely used for topical treatm

7 k-benefit balance seems to be acceptable for currently licensed anti-B cell agents, additional studie

8 While currently licensed antiviral drugs are critical tools, d

9 Compared to currently licensed assays, an ELISA incorporating a comb

10 cine to protect infants too young to receive currently licensed attenuated measles vaccines.

11 butable to carcinogenic HPV16/18 targeted by currently licensed bivalent and quadrivalent HPV vaccine

12 se in domestic swine and wild boar for which currently licensed commercial vaccines are only availabl

13 Currently licensed dengue vaccines do not induce long-te

14 For some drugs, higher than currently licensed doses might be tested in further tria

15 However, the currently licensed Dryvax vaccine, despite its documente

16 To provide a review of currently licensed enteric vaccines and their efficacy b

17 e, immunogenic, and highly protective and is currently licensed for human use in Argentina.

18 loride, a potassium sparing diuretic that is currently licensed for hypertension and congestive cardi

19 n adjuvants such as alum and MF59, which are currently licensed for influenza or other vaccines.

20 The majority of vaccines currently licensed for poultry health include both modif

21 ile are a health threat, yet no products are currently licensed for prevention of primary C difficile

22 3-carboxamide) is a nontoxic antiviral agent currently licensed for the treatment of severe RSV lower

23 like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes

24 Neonicotinoids are currently licensed for use in 120 countries, making accu

25 Docetaxel is currently licensed for use in a variety of malignancies,

26 at the combination of two adjuvants that are currently licensed for use in humans can be used to prim

27 However, currently licensed human vaccines are subtype-specific a

28 The vast majority of currently licensed human vaccines work on the basis of l

29 The currently licensed imaging modalities are limited by lac

30 uvanted recombinant zoster vaccine, which is currently licensed in certain countries for adults aged

31 tarix, a monovalent human rotavirus, are now currently licensed in many countries.

32 same methods that have been used to generate currently licensed inactivated H5N1 vaccines, we were ab

33 The potency of all currently licensed inactivated influenza viral vaccines

34 ed serious concerns regarding the utility of currently licensed inactivated influenza virus vaccines

35 as promising single-dose vaccines to replace currently licensed inactivated RV-based vaccines.

36 This review focuses on how currently licensed influenza vaccines are generated in t

37 unological bases for the efficacies of the 2 currently licensed influenza vaccines, live attenuated i

38 ve immune response and the main component of currently licensed influenza vaccines.

39 Currently licensed influenza virus vaccines rely on the

40 The currently licensed LAM test, Alere Determine TB LAM Ag (

41 Currently licensed nonstandardized allergen extracts wer

42 lored whether higher or lower doses than the currently licensed ones might be more appropriate, and d

43 olerated with a safety profile comparable to currently licensed pneumococcal vaccines and generates I

44 The currently licensed polysaccharide vaccine provides 60 to

45 oligosaccharides may offer no advantage over currently licensed preparations containing unconjugated

46 risk of intussusception (IS) associated with currently licensed rotavirus vaccines (RV1 [Rotarix; GSK

47 Finally, we confirm that currently licensed seasonal influenza vaccines can boost

48 Currently, licensed seasonal influenza vaccines display

49 ressing a non-vaccine type (according to the currently licensed seven-valent conjugate vaccine).

50 The exploratory analysis of currently licensed sofosbuvir treatment regimens found t

51 species appear to be less susceptible to the currently licensed systemic antifungal agents, with the

52 this end, we evaluated the performance of 12 currently licensed tests and 1 in-house HIV test (6 EIA,

53 e that alternative algorithm strategies with currently licensed tests compare favorably with the conv

54 ted States, 2 types of influenza vaccine are currently licensed: trivalent inactivated influenza vacc

55 ar short-term immunological responses to the currently licensed two-dose regimen.

56 vailable, has few toxic side effects, and is currently licensed under the name Elmiron for the treatm

57 However, the currently licensed vaccine is poorly immunogenic in infa

58 ses can be constructed within the context of currently licensed vaccine platforms.

59 No currently licensed vaccine reliably prevents pulmonary t

60 ains a serious bioterrorism concern, and the currently licensed vaccine remains an incomplete solutio

61 needed to overcome the disadvantages of the currently licensed vaccine strains that restrict their u

62 Currently licensed vaccine strains used in animals are u

63 by the limited and variable efficacy of the currently licensed vaccine, Bacille Calmette-Guerin (BCG

64 ng pulmonary infection for which there is no currently licensed vaccine.

65 rotection for many human vaccines, including currently licensed vaccines against flaviviruses.

66 Currently licensed vaccines against the common otopathog

67 The three currently licensed vaccines contain virus-like particles

68 Two currently licensed vaccines have been successful in redu

69 of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-r

70 Updated data on the effectiveness of currently licensed vaccines in this population are neede

71 Although most currently licensed vaccines provide protection via the i

72 thogenesis and disease progression, evaluate currently licensed vaccines, and develop improved vaccin

73 eligibility, availability, and efficacies of currently licensed vaccines, and review the results of r

74 rategies are needed to improve coverage with currently licensed vaccines.

75 immunosenescence and the immune response to currently licensed vaccines.

76 evidence of the comparative effectiveness of currently licensed vaccines.

77 protection against pneumococcal disease than currently licensed vaccines.

78 All currently licensed yellow fever (YF) vaccines are propag